Abstract
New technology is one of the primary drivers for increased healthcare costs in the United States. Both physician and industry play important roles in the development, adoption, utilization and choice of new technologies. The Federal Drug Administration regulates new drugs and new medical devices, but healthcare technology assessment remains limited. Healthcare technology assessment originated in federal agencies; today it is decentralized with increasing private sector efforts. Innovation is left to free market forces, including direct to consumer marketing and consumer choice. But to be fair to the consumer, he/she must have free knowledge of all the risks and benefits of a new technology in order to make an informed choice. Physicians, institutions and industry need to work together by providing proven, safe, clinically effective and cost effective new technologies, which require valid pre-market clinical trials and post-market continued surveillance with national and international registries allowing full transparency of new products to the consumer—the patient.
References
Arbuckle, B (2006) Device maker pricing has big impact on America’s healthcare bill. http://www.healthleadersmedia.com. 24 May
Bacin A, Stratton K, Burke SP (eds) (2006) Committee on the assessment of the U.S. drug safety system report: the future of drug safety: promoting and protecting the health of the public. National Academies, Washington http://www.IOM@edu/cms/3793/26341?37329.aspx. 5 October
Bal BS, Haltom D, Aleto E, Barrett M (2005) Early complications of primary total hip replacement performed with a two-incision minimally invasive technique. J Bone Jt Surg A 88A(Suppl):221–233
Bhattacharyya T, Yeon H, Harris MB (2005) The medical-legal aspects of informed consent in orthopaedic surgery. J Bone Jt Surg A 87A:2395–2400
Bhattacharyya T, Yeon H, Harris MB (2005) The medical-legal aspects of informed consent in orthopaedic surgery. J Bone Jt Surg A 87A:2399
Bozic KJ, Hansen E (2006) The impact of disruptive innovations in orthopaedic surgery. Orthop J Harvard Med School 8:37–39
Bozic KJ, Morshed S, Silverstein MD, Rubash HE, Kahn JG (2006) Use of cost-effectiveness analysis to evaluate new technologies in orthopaedics. The case of alternative bearing surfaces in total hip arthroplasty. J Bone Jt Surg A 88A:706–714
Bozic KJ, Pierce RG, Herndon JH (2004) Health care technology assessment. J Bone Jt Surg A 86A:1305–1314
Brennan TA, Leape LL, Laird NM, Nan M et al (1991) Incidence of adverse events and negligence in hospitalized patients: results of the Harvard medical practice study I. N Engl J Med 324:370–376
Callaghan JJ, Crowninshield RD, Greenwald AS, Lieberman JR, Rosenberg AL, Lewellan DG (2005) Introducing technology into orthopaedic practice. How should it be done? J Bone Jt Surg A 87A:1146–1158
Cherkin DC, Deyo RA, Loeser JD, Bush T, Waddell G (1994) An international comparison of back surgery rates. Spine 19:1201–1206
Christensen CM (2000) Will disruptive innovations cure healthcare? Harvard Bus Rev, September–October, pp 102–111
Deyo R (1991) Fads in the treatment of low back pain. N Engl J Med 325:1039–1045
Eisenberg JM, Zarin D (2002) Health technology assessment in the United States. Past, present, and future. Int J Technol Assess Health Care 18(2):192–198
Feeny D (1989) Technology assessment and the cost of healthcare. J Tech Assess Health Care 5:559–575
Frankle M, Levy JC, Pupello D, Siegal S, Saleem A, Mighell M, Vasey M (2005) The reverse shoulder prosthesis for glenohumeral arthritis associated with severe rotator cuff deficiency. A minimum two-year follow-up study of sixty patients. J Bone Jt Surg A 87A:1697–1705
Garber AM (2006) The price of growth in the medical-device industry. N Engl J Med 355:337–339
Gewande AA, Thomas EJ, Zinner MJ, Brennan TA (1999) The incidence and nature of surgical adverse events in Colorado and Utah in 1992. Surgery 126:66–75
Gillespie WJ, Pekarsky B, O’Connell DL (1995) Evaluation of new technologies for total hip replacement. Economic modeling and clinical trials. J Bone Jt Surg B 77B:528–533
Herzlinger, RE (2006) Why innovation in healthcare is so hard. Harvard Bus Rev, May, pp 58–66
Institute of Medicine (2006) http://www.iom@nas.edu
Lewellan DG (2005) Why new technologies should be submitted to the scientific review process before general implementation. In the American Orthopaedic Association symposium: introducing new technology into orthopaedic practice. How should it be done? J Bone Jt Surg A 87A:1157
Malchau H (2000) Introducing new technology: a stepwise algorithm. Spine 25:285
Maloney WJ (2001) National joint replacement registries: has the truth come? J Bone Jt Surg A 83A:1582–1585
Maynard A (1991) The relevance of health economics to health promotion. WHO Reg Publ Eur Ser 37:29–54
Millenson ML (1999) Demanding medical excellence: doctors and accountability in the information age. University of Chicago Press, Chicago
National Information Center on Health Services Research and Health Care Technology HTA 101: selected issues in HTA. National Institutes of Health. Available at http://www.nlm,gov/nichsr/hta101/ta101012.html. Accessed, 26 November 2006
Newmann PJ, Rosen AB, Weinstein MC (2006) Medicare and cost-effectivenss analysis. N Engl J Med 353:1516–1522
Roder C, El-Kerdi A, Eggli S, Aebi M (2004) A centralized total joint registry using web-based technologies. J Bone Jt Surg A 86A:2077–2080
Royal HD (1994) Technology assessment: scientific challenges. Am J Roentgenol 163(3):503–507
Tang N, Eisenberg JM, Meyer GS (2004) The roles of government in improving health care quality and safety. Jt Comm J Qual Saf 30(1):47–55
United States Government Accountability Office (GAO) Report (2006) Drug safety. Improvement needed in FDA’s postmarket decision-making and oversight process. GAO-06-402 March, pp 1–38
Weinstein JN (2003) Emerging technology in the spine. Should we rethink the past or move forward in spite of the past? Spine 28:51
Weinstein JN (2006) An altruistic approach to clinical trials. The National Clinical Trials Consortium (NCTC). Spine 31:1–3
Weinstein JN (2006) An altruistic approach to clinical trials. The National Clinical Trials Consortium (NCTC). Spine 31:1
Weinstein JN (2006) An altruistic approach to clinical trials. The National Clinical Trials Consortium (NCTC). Spine 31:2
Weinstein JN (2006) An altruistic approach to clinical trials. The National Clinical Trials Consortium (NCTC). J Bone Jt Surg A 88A:1396
Wilson RM, Harrison BT, Gibberd RW, Hamilton JD (1999) An analysis of the causes of adverse events from the quality in Australian health care study. Med J Aust 170:411–415
Wong DA (2006) AAOS member patient safety survey: a first look. Bull Am Acad Orthop Surg 54:19–20
Author information
Authors and Affiliations
Corresponding author
Additional information
No grant support.
An erratum to this article can be found at http://dx.doi.org/10.1007/s00586-007-0441-8
Rights and permissions
About this article
Cite this article
Herndon, J.H., Hwang, R. & Bozic, K.H. Healthcare technology and technology assessment. Eur Spine J 16, 1293–1302 (2007). https://doi.org/10.1007/s00586-007-0369-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00586-007-0369-z